Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. (Q38544844)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

review article

1 reference

title

Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Massimo Milione

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Sara Pusceddu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Alice Lorenzoni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Marco Maccauro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Vincenzo Mazzaferro

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Fabrizio Festinese

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Cristina Bregant

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Laura Concas

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Barbara Formisano

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Livia Leuzzi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Roberto Buzzoni

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

1947-1959

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

19 February 2020

cites work

1 reference

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

21 January 2018

1 reference

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

21 January 2018

1 reference

Practical markers used in the diagnosis of neuroendocrine tumors

21 January 2018

1 reference

21 January 2018

1 reference

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors

21 January 2018

1 reference

Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

21 January 2018

1 reference

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

21 January 2018

1 reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

21 January 2018

1 reference

Pasireotide (SOM230): development, mechanism of action and potential applications

21 January 2018

1 reference

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

21 January 2018

1 reference

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

21 January 2018

1 reference

Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms

21 January 2018

1 reference

Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view

21 January 2018

1 reference

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study

21 January 2018

1 reference

Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment

21 January 2018

1 reference

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.

21 January 2018

1 reference

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging

21 January 2018

1 reference

Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.

21 January 2018

1 reference

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.

21 January 2018

1 reference

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

21 January 2018

1 reference

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study

21 January 2018

1 reference

Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

21 January 2018

1 reference

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.15.86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26161929%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference